Skip to main content

Original Research

Original Research
Key Features of Academic Detailing: Development of an Expert Consensus Using the Delphi Method
James S Yeh, MD, Thomas J. Van Hoof, MD, EdD, Michael A. Fischer, MD, MS
Stakeholder Perspective
Improving Patient Outcomes and Drug Prescribing Cost-Effectiveness Through Academic Detailing
by Jack E. Fincham, PhD, RPh
Read More
Original Research, Practice Management
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Lisa M. Bloudek, PharmD, MS, Dinara Makenbaeva, MD, MBA, Michael Eaddy, PharmD, PhD
Stakeholder Perspective
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
by Gary Branning, MBA
Read More
Original Research
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice
Norman E. Lepor, MD, Dean J. Kereiakes, MD
Read More
Original Research
Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis
Joseph Tkacz, MS, Michael P. Ingham, MSc, Brenna L. Brady, PhD, Roxanne Meyer, PharmD, Charles Ruetsch, PhD
Stakeholder Perspective
You Cannot Manage What You Cannot Measure
by Sharon Glave Frazee, PhD, MPH
Read More
Original Research
Reviewing the Unmet Needs of Patients with Multiple Sclerosis
Stanton R. Mehr, Marj P. Zimmerman, BSPharm, MS
Read More
Original Research
How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?
Marj P. Zimmerman, BSPharm, MS
Read More
Original Research
The Latest Innovations in the Drug Pipeline for Multiple Sclerosis
Lea Radick, Stanton R. Mehr
Read More
Original Research
Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment
Gary M. Owens, MD
Stakeholder Perspective
Closing Gaps in Health Plan Performance with Stakeholder Collaboration
by F. Randy Vogenberg, PhD, FASHP
Read More
Original Research, Practice Management
Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease
Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD
Stakeholder Perspective
A Teachable Moment in Health Benefits Design
by Michael F. Murphy, MD, PhD
Read More
Original Research
Longitudinal Commercial Claims–Based Cost Analysis of Diabetic Retinopathy Screening Patterns
Kathryn Fitch, RN, MEd, Thomas Weisman, MD,MBA, Tyler Engel, ASA, MAAA, Adam Turpcu, PhD, Helen Blumen, MD, MBA, Yamina Rajput, MS, Purav Dave, MS, MBA
Stakeholder Perspective
The Economics of Screening Patients with Diabetes for Diabetic Retinopathy
by Sharon Glave Frazee, PhD, MPH
Read More
Page 13 of 21
Results 121 - 130 of 209